iSpecimen Inc.

For the quarter ended March 31, 2024, revenue was approximately $2.3 million versus approximately $3 million in the prior-year quarter. Specimen count fell 39% to 5,241 from 8,629, while average selling price per specimen increased 28% to $437 from about $342. Cost of revenue declined 13% to about $1 million from about $1.1 million, technology expenses rose 9% to approximately $900,000, sales and marketing expenses declined 31% to about $660,000, and general and administrative expenses increased 16% to about $2.1 million. As of March 31, 2024, cash and cash equivalents were about $2.1 million and available-for-sale securities were about $466,000, for a combined total of about $2.6 million, versus $5 million of cash at December 31, 2023. Management said $2.5 million of cash was used in the quarter, including $1.2 million tied to one-time consulting, legal, tax, and ATM-related expenses; excluding those items, burn would have been about $1.2 million, or a little over $400,000 per month. No formal revenue or EPS guidance was given, but management said it is setting the stage for revenue growth in the second half of 2024 and beyond.

Tracy Curley framed the quarter as a transition toward a more disciplined, scalable operating model. She emphasized strategic spending cuts, a lower cash burn rate, and a focus on core market opportunities, saying these actions are intended to create a runway for growth later in 2024 and beyond. Her tone was upbeat and confident about the Next-Day Quotes program and the company’s ability to improve operations and top-line momentum.

Curley, who also served as CFO on the call, highlighted the financial impact of restructuring and cost control. She said compensation costs were down 41% year over year and technology costs were down 66% versus Q1 2023, and she noted that $1.2 million of the quarter’s $2.5 million cash use came from one-time consulting, legal, tax, and ATM-related costs. She also pointed to a combined cash and securities balance of about $2.6 million at quarter-end and said the company may seek additional funding through public equity and other sources if needed.

Analysts focused on whether the sharp improvement in Next-Day Quotes conversion is sustainable and how embedded coordinators could accelerate growth. Management said the improvement is sustainable and explained that better supplier data, more inventory visibility, and additional sites in the program should support continued progress; Leslie Hoyt said 3 sites were added to the program in the last 2 months. A second question asked whether reducing suppliers hurts sample access; management said the opposite is happening, with fewer but better suppliers providing more capabilities, more supply, and better-quality specimen access. On bird flu, management said they have not yet seen specific demand but would follow up, while noting ongoing demand for flu A and B samples.